Last reviewed · How we verify

Improving Resorption of Radiopaque Agents in Subcutaneous Urography — Treatment Landscape & Competitive Intelligence

Improving Resorption of Radiopaque Agents in Subcutaneous Urography (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Improving Resorption of Radiopaque Agents in Subcutaneous Urography, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Recombinant antithrombin (rhAT) Recombinant antithrombin (rhAT) Mayo Clinic Dispersion agent; enzyme Hyaluronic acid and connective tissue polysaccharides

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Mayo Clinic · 1 drug in Improving Resorption of Radiopaque Agents in Subcutaneous Urography

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Improving Resorption of Radiopaque Agents in Subcutaneous Urography:

Cite this brief

Drug Landscape (2026). Improving Resorption of Radiopaque Agents in Subcutaneous Urography — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/improving-resorption-of-radiopaque-agents-in-subcutaneous-urography. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing